{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-029517","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.777307+00:00","generated_at":"2026-05-31T15:31:11.606816+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Imunon reports Phase 2 OVATION 2 trial: 11.1-month OS increase in advanced ovarian cancer with IMNN-001","bullets":["Median OS improved by 11.1 months (40.5 vs 29.4) in ITT; HR 0.74 (0.42-1.30).","In patients receiving ≥3 doses, OS extended by 15.7 months (45.1 vs 29.4); HR 0.64.","PARP inhibitor subgroup: median OS not reached in IMNN-001 arm vs 37.1 months; HR 0.41.","PFS primary endpoint: 3-month improvement (14.9 vs 11.9); HR 0.79.","Company plans registrational Phase 3 study to begin in Q1 2025; End-of-Phase 2 meeting with FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-029517","json":"https://secwatch.observer/filing/0001493152-24-029517.json","markdown":"https://secwatch.observer/filing/0001493152-24-029517.md","text":"https://secwatch.observer/filing/0001493152-24-029517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315224029517/0001493152-24-029517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315224029517/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:31:11.606816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}